



## UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

June 5, 2024

- Presentation June 11, 2024 at 3:20 PM ET -

PRINCETON, N.J.--(BUSINESS WIRE)--Jun. 5, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a fireside chat at the 45<sup>th</sup> Annual Goldman Sachs Global Healthcare Conference to take place June 10-13, 2024.

### Goldman Sachs 45<sup>th</sup> Annual Healthcare Conference

Date/ time: June 11, 2024 at 3:20 PM ET  
Format: Fireside Chat  
Location: Miami, FL  
Webcast Link: [here](#)

A webcast from the conference will also be available via the Investors section of UroGen's corporate website, <https://investors.urogen.com>. A replay will be available for approximately 90 days.

### About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. To learn more, visit [www.UroGen.com](http://www.UroGen.com) or follow us on X (Twitter), @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240605807048/en/): <https://www.businesswire.com/news/home/20240605807048/en/>

### INVESTOR CONTACT:

Vincent Perrone  
Senior Director, Investor Relations  
[vincent.perrone@urogen.com](mailto:vincent.perrone@urogen.com)  
609-460-3588 ext. 1093

### MEDIA CONTACT:

Cindy Romano  
Director, Corporate Communications  
[cindy.romano@urogen.com](mailto:cindy.romano@urogen.com)  
609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.